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ABSTRACT
As trachoma programs move towards eliminating trachoma as a public health problem, the number 
of surveys necessary to evaluate the status of trachomatous trichiasis (TT) increases. Currently, the 
World Health Organization endorses a district-level population-based prevalence survey for tra-
choma that involves a two-stage cluster design. We explored the validity of implementing this 
survey design in larger geographic areas to gain cost efficiencies. We evaluated the change in 
precision due to combining geographically contiguous and homogenous districts into single 
evaluation units (EUs) and modulating the sample size by running simulations on existing datasets. 
Preliminary findings from two opportunities in Tanzania show variability in the appropriateness in 
conducting this survey across larger geographies. These preliminary findings stress the importance 
of determining what is meant by homogeneity in terms of TT before combining multiple districts 
into a single EU.
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Background
Trachoma, a neglected tropical disease, is caused by 
repeated ocular Chlamydia trachomatis infection lead-
ing to chronic inflammation of the tarsal conjunctiva; 
this inflammation is defined as trachomatous inflamma-
tion–follicular (TF).1 TF may cause conjunctival scar-
ring, which in turn may lead to inward turning of 
eyelashes that can touch the eye. The eyelashes may 
damage the cornea, and lead to corneal opacity and 
blindness. This morbidity stage of trachoma generally 
occurs in adulthood. The presence of eyelashes touching 
the eye is called trachomatous trichiasis (TT).
Trachoma is targeted for elimination as a public 
health problem,2 defined as district level prevalence of 
TF below 5% in children aged 1–9 years and of TT 
unknown to the health system below 0.2% in adults 
aged 15 years and older.3,4 National programs of ende-
mic countries employ the intervention strategy, called 
SAFE, which involves (S) surgery to correct trichiasis; 
(A) mass drug administration of antibiotics; and sanita-
tion and hygiene improvements, focusing on (F) facial 
cleanliness and (E) environmental improvement.2
To inform decision-making and measure against 
elimination targets, the World Health Organization 
(WHO) endorses a population-based prevalence survey 
(PBPS) using two-stage cluster sampling.5,6 The recom-
mended survey design involves (i) selection of villages as 
the first sampling stage; and (ii) selection of households 
as the second sampling stage. This method is powered to 
estimate prevalence of TF and TT at the evaluation unit 
(EU) level (typically a district of 100,000–250,00 people). 
PBPSs require considerable resources, typically costing 
between 6,500 USD and 11,000 USD per EU.7
The 4th Global Scientific Meeting on Trachoma 
(GSM4) report provides alternative options for country 
programs to demonstrate that TT elimination targets 
have been met. These options include conducting full 
geographic coverage case-finding and trichiasis service 
delivery, and combining data from adjacent EUs to 
create a larger EU.8The larger geographic area resulting 
from combining adjacent EUs may contain greater het-
erogeneity in terms of TT distribution. However, an 
increased number of clusters across this larger geogra-
phy may also decrease the sampling error.
The GSM4 report section 5.4.iii, states that “ . . . . 
national programmes may use . . . a combination of 
data from multiple adjacent evaluation units. 
Professional statistical
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advice should be sought as to the best way to combine 
data from multiple evaluation units, with guidance sub-
sequently given to national programmes and their 
partners”.8 As trachoma programs move towards elim-
inating trachoma as a public health problem, the num-
ber of surveys necessary to evaluate the status of TT 
increases – absorbing large portions of country pro-
gram’s budgets. Here, we explore the validity of con-
ducting the currently endorsed survey design within 
super EUs (created by combining geographically contig-
uous and homogenous districts) and evaluated the 




With guidance from the Tanzania NTD Control 
Program, we selected two opportunities to explore the 
consolidation of data from geographically contiguous 
districts. The first opportunity combines Babati 
District Council (DC) and Mbulu DC, both in 
Manyara Region, into a super EU; the second combines 
Iringa DC, Kilolo DC and Mufindi DC, all in Iringa 
Region, into a super EU. Baseline surveys conducted in 
2004 (Iringa DC/Kilolo DC), 2012 (Babati DC and 
Mbulu DC) and 2014 (Mufindi DC) indicated TF 
below the elimination threshold and TT above the elim-
ination threshold (Table 1).9 Additionally, none of these 
districts had any active TT outreach supported by part-
ners in the years between the baseline surveys and the 
TT-only survey. These baseline surveys were conducted 
prior to the refinement of TT indicator to “TT unknown 
to the health system” and therefore baseline TT preva-
lence may be overestimated.
Data used for the analysis presented here were 
derived from PBPSs conducted in 2018 through the 
Tropical Data system.10 They followed a two-stage clus-
ter sampling strategy, and each included 30 villages 
(Figure 1 and 2).
Analysis
In this analysis, we defined a case of TT as an individual 
aged at least 15 years old with presence of upper lid 
trichiasis in either eye.8 We defined a case of TT 
unknown to the health system as a TT case that had not 
previously been offered surgery or epilation. All analyses 
were performed in R v3.4.411. For each village, we calcu-
lated the proportion of all TT cases and unknown to the 
health system found within each five-year age/sex group 
and weighted these proportions according to the expected 
proportion of residents with that age and sex. The 
expected population pyramid was derived from the 
United Nations World Population Prospective.11 The 
village level prevalence was calculated as the sum of the 
weighted proportions for each age/sex group.
To derive 95% confidence intervals for each district, 
we bootstrapped (randomly sampled with replacement) 
the village level prevalence dataset with 10,000 replica-
tions. The 2.5th and 97.5th centiles of the order means 
from the bootstrap were used as the lower and upper 
95% confidence interval bounds. We then re-classified 
the villages to create super EUs and again bootstrapped 
the village level prevalence dataset with 10,000 replica-
tions and took the 2.5th and 97.5th centiles of the order 
means as the lower and upper 95% confidence interval 
bounds.
We then modulated the sample size of the super EUs 
through reducing the number of villages in the boot-
strap. We bootstrapped with replacement over 10,000 
replications, three additional times: first randomly sam-
pling with replacement 100%, then 90%, then 80% of the 
total number of villages in each resample.
We compared the results by first assessing the pro-
grammatic decision that resulted from comparing the 
mean in both the districts and super EUs with the 
elimination threshold of 0.2% unknown to the health 
system. We then assessed the change in precision 
between the districts and super EUs through evaluating 
the width of the confidence intervals. Finally, we exam-




The observed adjusted mean of the district level preva-
lences are at or above the elimination threshold of 0.2% 
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*In 2004 these two districts were a single district and surveyed as such. They 
were divided into two districts in 2014. The 2004 TF estimates have not 
been published and so the value presented here is from the available 
categorical data from the global atlas of trachoma (https://www.tracho 
maatlas.org).
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Figure 1. Distribution of first-stage village data points in Babati DC and Mbulu DC.
Figure 2. Distribution of first-stage village data points in Iringa DC, Kilolo DC, and Mufindi DC.
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unknown to the health system in both Babati DC and 
Mbulu DC (Table 2). The super EU mean estimate is 
also above the elimination threshold. When the districts 
are combined into a super EU, the confidence intervals 
and interquartile range tighten, diluting the influence of 
outliers.
In Opportunity 1, as the sample size was reduced in 
the super EU, the mean TT prevalence remained stable 
and the confidence intervals widened (Table 3 and 
Figure 3). Because the mean point prevalence is used 
for decision-making, the simulations suggest that redu-
cing the sample sizes does not change the decision to 
continue intervention. However, as the sample size 
decreases so does the precision. There is no difference 
between the mean prevalence point estimate of all TT 
cases and unknown to the health system cases in this 
opportunity.
Opportunity 2
The observed adjusted mean of the district level preva-
lences are below the elimination threshold of 0.2% 
unknown to the health system in both Kilolo DC and 
Mufindi DC (Table 4). However, the mean estimate in 
Iringa DC and the super EU are above the elimination 
threshold. When the districts are combined into a super 
EU the confidence intervals and interquartile range 
tighten, and the higher-prevalence villages in Iringa 
DC pull the mean to the threshold.
In Opportunity 2, as the sample size was reduced in 
the super EU, the mean TT prevalence increases, and the 
confidence intervals widen. However, the mean remains 
above the elimination threshold (Table 5 and Figure 4). 
This suggests that reducing the sample sizes does not 
change the decision to continue intervention for the 
super EU.
Table 2. Opportunity 1, 2018 unknown to the health system 
prevalence estimates.
District










0.27% 0.17% 0.01% 0.65%
Mbulu 
DC
0.20% 0.17% 0.00% 0.57%
Super 
EU
0.24% 0.12% 0.03% 0.50%
Table 3. Opportunity 1, 2018 super EU unknown to the health 














60 100% 0.24% 0.12% 0.03% 0.50%
54 90% 0.24% 0.13% 0.02% 0.52%
48 80% 0.24% 0.13% 0.02% 0.52%
The confidence intervals for the 80% simulation are wider than the 90% 
simulation, due to the third decimal place in the lower bound.
Figure 3. Opportunity 1 distribution of super EU unknown to the health system bootstrap results with modulating sample sizes. 
Dashed lines represent 95% confidence intervals and the red dashed lines represent the mean; solid lines represent the elimination 
threshold of 0.2%.
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Discussion
The latest outcomes from the GSM4 provide a variety of 
options when assessing whether elimination thresholds 
have been met for TT.8 While many country programs 
chose geographic coverage case finding, there are some 
situations where a program may wish to use 
a combination of data from multiple adjacent districts 
to evaluate their progress. Here we aim to provide gui-
dance on when to combine EUs for country programs 
who choose this option. To employ this option, pro-
grams must first understand the implications of combin-
ing districts.
In our opportunities, we observed that combining 
geographically contiguous districts into a super EU and 
retaining the prescribed number of villages resulted in 
increased precision. However, we also found that our 
super EUs do not trigger consistent programmatic deci-
sions. In Opportunity 1, combining Babati DC and 
Mbulu DC into a super EU triggers the continuation of 
implementing TT interventions. However, in 
Opportunity 2, combining Iringa DC, Kilolo DC and 
Mufindi DC into as super EU results in unnecessarily 
continuing TT interventions in Kilolo DC and Mufindi 
DC. In all cases, however, the bootstrapped 95% con-
fidence intervals cross over the elimination threshold. It 
is standard practice for trachoma programs to make 
their decisions based on the observed point estimates 
rather than the confidence intervals, but they should also 
consider the loss of precision represented by the broad-
ening of confidence intervals.
In both opportunities, reducing the number of vil-
lages included in the super EU did not change the pro-
grammatic decision. Therefore, if programs could 
Table 4. Opportunity 2, 2018 prevalence estimates.
Unknown to the health system All cases
District TT prevalence Standard Error 95% CI (lower) 95% CI (upper) TT prevalence Standard Error 95% CI (lower) 95% CI (upper)
Iringa DC 0.30% 0.10% 0.13% 0.51% 0.33% 0.10% 0.16% 0.54%
Kilolo DC 0.15% 0.13% 0.00% 0.43% 0.15% 0.13% 0.00% 0.44%
Mufindi DC 0.15% 0.08% 0.03% 0.32% 0.19% 0.08% 0.05% 0.37%
Super EU 0.20% 0.06% 0.10% 0.33% 0.23% 0.06% 0.12% 0.35%















90 100% 0.20% 0.06% 0.10% 0.33%
81 90% 0.24% 0.11% 0.06% 0.47%
74 80% 0.24% 0.11% 0.05% 0.48%
Figure 4. Opportunity 2 distribution of super EU unknown to the health system bootstrap results with modulating sample sizes. 
Dashed lines represent 95% confidence intervals and the red dashed lines represent the mean; solid lines represent the elimination 
threshold of 0.2%.
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accurately classify EUs as homogeneous, they might gain 
some cost efficiencies due to the reduction in the num-
ber of clusters in a super EU.
We relied on baseline TF and overall TT prevalence to 
suggest contemporary TT homogeneity across our dis-
tricts. At baseline, TF was below the elimination thresh-
old in all included districts. We therefore assumed TT 
prevalence would reduce at a relatively similar rate across 
districts. However, our opportunity 2 results suggest that 
additional factors may influence the rate of reduction in 
TT prevalence and should be taken into consideration 
when classifying districts as homogenous. Additional 
factors to include in future work could be topography, 
population density, demographics, and infrastructure. 
Furthermore, exploration of the variation in village- 
level TT prevalence at baseline could provide valuable 
insight into what to expect in contemporary surveys.
Understanding both the coverage of and quality of past 
TT interventions in each area would provide key informa-
tion to help determine TT homogeneity across districts. 
Regardless of the challenges associated with reaching 
patients, a critical component affecting impact is quality 
of services provided. Numerous studies have highlighted 
concerns around post-operative TT12–20 (PTT) and the 
effect that high rates of PTT in an area can have on com-
munity members’ willingness to be screened by a local case 
finder or by the district health system. A qualitative study 
in Tanzania found that people were more reluctant to 
attend a surgical facility due to witnessing poor TT surgical 
outcomes of their neighbours.21 Thus, prevalence of TT 
unknown to the health system in areas with historically 
high rates of PTT may reduce more slowly than other 
districts.
We aimed to provide guidance to country pro-
grams who wish to combine districts into super 
EUs through evaluating change in precision when 
combining districts and reducing the number of vil-
lages. However, this analysis highlighted a more gen-
eral question of what is meant by homogeneity in 
terms of TT. Following WHO intervention recom-
mendations, in our super EU opportunities two dis-
tricts would receive more than required public health 
interventions. This analysis additionally suggests that 
while increased precision may be gained by averaging 
in neighbouring survey data this may not impact the 
EU’s status in meeting elimination thresholds. GSM4 
includes an option of full geographic coverage case 
finding and service delivery for determining elimina-
tion. This approach is in line with providing access 
to service and so may be the method chosen by many 
programs. However, if programs wish to combine 
districts into super EUs, further work is needed to 
determine if there are additional indicators that could 
consistently identify TT homogeneity across districts.
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